US” pharmaceutical company obtains licensing rights from IMTECHFebruary 24th, 2009 - 4:01 pm ICT by ANI
New Delhi, Feb. 24 (ANI): The US-based Nostrum Pharmaceuticals has obtained worldwide licensing rights from the Indian-based Institute of Microbial Technology (IMTECH), to develop and commercialise Caerulomycin A, and its proprietary derivatives and analogues for their novel indication and immunosuppression.
IMTECH is a constituent laboratory of the Council of Scientific and Industrial Research (CSIR),
Significance of the deal lies in potential of Caerulomycin to develop into a blockbuster drug to be used to prevent organ transplantation rejection and diseases such as certain autoimmune disorders where immunosuppression is the key to the mitigation of the symptoms.
Nirmal Mulye, Nostrum President and Girish Sahni, Director, IMTECH signed the licensing agreement in the presence of Union Science and Technology Minister Kapil Sibal. “On the basis of the molecule which we have discovered, we have signed an agreement with the company and it seems we are going to benefit from it and if in future if we become successful then it would become a multi billion dollar blockbuster drug. We hope that we will make a drug, which will be useful for people, cheap and accessible and also CSIR and our partners will benefit from it,” said Sibal.
Girish Sahni, Director, IMTECH, said, “the molecule discovered would be used in tissue transplantation like in kidney, heart. Today the drugs available are very expensive and it’’s a big challenge to discover a new drug. It definitely is a proud moment.”
This is the second molecule that IMTECH has under license with Nostrum, the first being a novel thrombolytic clot-buster protein known as SMRX11. (ANI)
- Controller clears clot-buster drug for human trial - Aug 17, 2012
- Bharat Biotech begins phase III trials of clot-busting drug - Feb 04, 2011
- Chandigarh Research Institute develops medicine for clots busting linked to heart attacks - Aug 08, 2009
- CSIR launches new cardiac drug in Indian market - Jul 10, 2009
- Genes can tell which kidney transplant recipients don't need lifelong drugs - May 25, 2010
- Altered 'ecstasy' could kill some blood cancers - Oct 06, 2011
- New test quickly detects kidney transplant rejection - Feb 18, 2010
- Delhi homemaker gets new heart - May 31, 2011
- Cholesterol-lowering drugs may improve blood flow after stroke - Apr 27, 2011
- Mechanism behind organ transplant rejection uncovered - Nov 19, 2010
- Britain to conduct first voicebox transplant - Jun 20, 2011
- Now, a blood test to detect organ transplant rejection - Sep 25, 2010
- Licenses, spectrum de-linked in new telecom policy - Apr 11, 2011
- India decodes TB bacteria, paves way for new drug - Apr 11, 2010
- Second molecule in Alzheimer's toxic duo identified - Feb 04, 2011
Tags: analogues, autoimmune disorders, blockbuster drug, clot buster, constituent laboratory, imtech, kapil sibal, licensing agreement, microbial technology, mitigation, molecule, New Delhi, organ transplantation, pharmaceutical company, proprietary derivatives, proud moment, rejection, science and technology, technology minister, tissue transplantation